Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Accelerate Diagnostics (NASDAQ:AXDXFree Report) in a research report sent to investors on Saturday morning. The brokerage issued a hold rating on the medical research company’s stock.

Several other equities research analysts also recently commented on AXDX. William Blair reiterated an outperform rating on shares of Accelerate Diagnostics in a report on Tuesday, April 2nd. Craig Hallum reduced their price target on shares of Accelerate Diagnostics from $2.00 to $1.00 and set a hold rating for the company in a research note on Monday, April 1st.

Check Out Our Latest Research Report on AXDX

Accelerate Diagnostics Stock Up 11.6 %

NASDAQ:AXDX opened at $0.86 on Friday. The stock has a market cap of $18.61 million, a price-to-earnings ratio of -0.18 and a beta of 0.52. The company’s 50 day moving average price is $0.99 and its 200-day moving average price is $3.14. Accelerate Diagnostics has a 52 week low of $0.73 and a 52 week high of $11.90.

Accelerate Diagnostics (NASDAQ:AXDXGet Free Report) last issued its earnings results on Thursday, March 28th. The medical research company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.27). The business had revenue of $3.03 million during the quarter, compared to analyst estimates of $3.80 million. As a group, sell-side analysts anticipate that Accelerate Diagnostics will post -2.27 earnings per share for the current year.

Institutional Trading of Accelerate Diagnostics

A number of hedge funds have recently bought and sold shares of the company. Swiss National Bank boosted its position in Accelerate Diagnostics by 19.0% in the first quarter. Swiss National Bank now owns 85,300 shares of the medical research company’s stock worth $123,000 after purchasing an additional 13,600 shares during the last quarter. JPMorgan Chase & Co. grew its position in Accelerate Diagnostics by 17.9% during the first quarter. JPMorgan Chase & Co. now owns 418,359 shares of the medical research company’s stock valued at $602,000 after buying an additional 63,513 shares during the period. HighTower Advisors LLC increased its holdings in Accelerate Diagnostics by 115.6% during the first quarter. HighTower Advisors LLC now owns 37,302 shares of the medical research company’s stock valued at $53,000 after buying an additional 20,000 shares during the last quarter. Bank of Montreal Can bought a new position in Accelerate Diagnostics in the first quarter worth approximately $27,000. Finally, Baird Financial Group Inc. boosted its stake in shares of Accelerate Diagnostics by 15.5% during the 1st quarter. Baird Financial Group Inc. now owns 1,741,547 shares of the medical research company’s stock worth $2,508,000 after acquiring an additional 233,478 shares during the last quarter. Hedge funds and other institutional investors own 17.14% of the company’s stock.

About Accelerate Diagnostics

(Get Free Report)

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.

Recommended Stories

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.